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Executive Summary 
Sample Characteristics 
The QLD EDRS sample was predominantly 
young, educated males. Cannabis and ecstasy 
were the drugs of choice nominated by the 
sample (28% and 23%, respectively), while 
cannabis and alcohol were the drugs used 
most often by the sample (54% and 21%, 
respectively).  
Ecstasy 
The ecstasy market has diversified over the 
past few years, with recent (i.e. past six 
months) use of ecstasy pills declining and use 
of capsules and crystal increasing (55%, 78% 
and 65% of the QLD sample, respectively). 
These changes may be partially explained by 
the differences in perceived purity, with ecstasy 
capsules and crystal reported to be of higher 
purity than pills and powder.  
Methamphetamine 
In 2019, 24% of the QLD sample reported 
recent use of methamphetamine (i.e. past six 
months), with crystal being the primary form 
used (16%), followed by powder (9%).  
Cocaine 
Recent use of cocaine has increased in recent 
years, with 67% of the sample reportedly using 
cocaine in the last six months. Most consumers 
reported infrequent use of the drug. Fifty-nine 
per cent of consumers believed that cocaine 
was ‘easy’ or ‘very easy’ to access.  
Ketamine, LSD & Mushrooms 
Recent use of ketamine and LSD has 
increased since monitoring began in 2003, with 
27% of the QLD sample reporting recent 
ketamine use and 53% of the QLD sample 
reporting recent LSD use in 2019. Use of 
mushrooms has also increased since 
monitoring began, but has remained stable in 
recent years, with 27% of participants reporting 
recent use. 
Cannabis 
Almost all participants (92%) in the 2019 QLD 
sample have recently used cannabis, 
continuing a consistently high rate of use in 
Queensland since reporting began in 2003. 
Twenty-seven per cent of the QLD sample 
reported daily use in 2019.  
New Psychoactive Substances (NPS) 
One-third of QLD participants (33%) reported 
recent use of at least one form of NPS in 2019. 
DMT and 2C-B were the most common NPS 
recently used (16% and 10%, respectively). 
Thirteen per cent of participants reported 
recent use of capsules with unknown contents 
and almost one-fifth (18%) reported using pills 
with unknown contents.  
Drug-Related Harms and Other Risks 
Ninety-one per cent of the QLD sample 
reported using depressants, cannabis and/or 
hallucinogens and dissociatives on their last 
occasion of stimulant use. One-fifth (22%) 
reported a non-fatal stimulant overdose, and 
39% reported a non-fatal depressant overdose 
in the past year. The proportion reporting 
injecting drug use remained low (10%), as did 
the number currently in drug treatment (9%).  
Almost two-thirds (62%) self-reported that they 
had experienced a mental health problem in 
the preceding six months, and 67% of this 
group had seen a mental health professional in 
the same period. Two-fifths (40%) reported 
engaging in drug dealing, and almost one-
quarter (24%) reported engaging in property 
crime in the past month. 
QUEENSLAND 2019 SAMPLE CHARACTERISTICS
OTHER DRUGS
DRUG TREATMENT AND MENTAL HEALTH
MODES OF PURCHASING
20 years 66%
Full time workUnemployedCurrent student
65%
13% 11%
In 2019, 100 people from 
Queensland participated in EDRS 
interviews.
The median age in 2019 was 20 
(IQR = 19-23), and 66% identified 
as male.
In the 2019 sample, 65% were 
students, 13% were unemployed, 
and 11% were employed full time.
Participants were recruited on the 
basis that they had consumed
ecstasy or other illicit stimulants at 
least monthly in the past 6 months.
2O192O18
27%28%
2O192O18
53%61%
2O192O18
40%
22%
2O192O18
56%57%
Past 6 month use of ketamine was 
reported by 27% of the 2019 EDRS 
sample, stable from 28% in 2018.
Past 6 month use of LSD was 
reported by 53% in 2019, down 
from  61% in the 2019 EDRS 
sample.
Past 6 month use of amyl nitrite 
increased from 22% in 2018 to 40% 
in the 2019 EDRS sample.
Past 6 month use of nitrous 
oxide (nangs) ws stable at 56% in 
2019 (57% in the 2018).
Anxiety: 78%
Depression: 72%
ADHD: 17%
67%
Of the 2019 EDRS sample 9%
reported that they were currently 
receiving drug treatment.
Over half of the Queensland 
sample (62%) self-reported that 
they had experienced a mental 
health problem in the previous 6 
months.
Of those who commented, the 
most common self-reported mental 
health concern was anxiety (78%), 
followed by depression (72%), and 
ADHD (17%).
Of those self-reporting a mental 
health problem, 67% reported 
seeing a mental health professional 
in the previous 6 months.
81% 82% 21%
In 2019, 81% of the EDRS sample reported 
buying drugs face to face in the previous 12 
months.
In 2019, 82% of the EDRS sample reported 
buying drugs off social networking applications 
in the previous 12 months.
In 2019, 21% of the EDRS sample reported 
buying drugs off the darknet in the previous 12 
months.
Ecstasy
Cocaine
Other stimulants
ECSTASY
METHAMPHETAMINE
COCAINE
CANNABIS
PowderCrystalCapsulesPills
55%
78%
22%
65%
2 Pills
2 Capsules
0.20 Grams
of Crystal
0.20 Grams
of Powder
Past 6 month use of ecstasy pills, 
capsules, crystal, and powder in 
2019.
Of those who had recently 
consumed ecstasy, 24% used it 
weekly or more often.
Median amounts of ecstasy
consumed in a ‘typical’ session 
using each form. 
Of those who could comment
91% perceived ecstasy capsules 
to be ‘easy’ or ‘very easy’ to 
obtain. 
CrystalPowder
9% 16%
67%
Snorted
24% of people in the Queensland 
EDRS sample had used 
methamphetaime in the previous 6 
months.
Of the entire sample, 9% had 
recently consumed powder, and 
16% crystal methamphetamine.
81% of people who had recently 
used crystal smoked it. Of those 
who had recently used powder, 
67% snorted it.
Of those who could comment
93% perceived crystal 
methmphetamine to be ‘easy’ 
or ‘very easy’ to obtain. 
97%
Snorted
67% of the entire sample used cocaine in the 
past 6 months.
Of people who had consumed cocaine in the 
last 6 months, 97% had snorted it.
Of those who could comment
59% perceived cocaine to be ‘easy’ or ‘very 
easy’ to obtain.
96%
Smoked
92% of the sample had used 
cannabis in the previous 6 months.
Of those who had consumed
cannabis recently, 75% reported 
weekly or more frequent use.
Of people who had consumed 
cannabis in the last 6 months, 
96% had smoked it.
Of those who could comment
88% perceived hydro to be 
‘easy’ or ‘very easy’ to obtain.
81%
Smoked
2O192O18
91%83%
93%
2O192O18
60% 59%
HydroBush
64%
2018 2018 20192019
67%
86% 88%
24%
M T SFTW S
75%
M T SFTW S
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Background 
The Ecstasy and Related Drugs Reporting System (EDRS) is an illicit drug monitoring system which 
has been conducted in all states and territories of Australia since 2003, and forms part of Drug Trends. 
The purpose is to provide a coordinated approach to monitoring the use, market features, and harms 
of ecstasy and related drugs. This includes drugs that are routinely used in the context of 
entertainment venues and other recreational locations, including ecstasy, methamphetamine, 
cocaine, new psychoactive substances, LSD (d-lysergic acid), and ketamine. The EDRS is designed 
to be sensitive to emerging trends, providing data in a timely manner rather than describing issues in 
extensive detail. It does this by studying a range of data sources, including data from annual 
interviews with people who regularly use ecstasy and other stimulants and from secondary analyses 
of routinely-collected indicator data. This report focuses on the key findings from the annual interview 
component of EDRS.  
Methods 
Full details of the methods for the annual interviews are available for download. To briefly summarise, 
participants were recruited primarily via internet postings, print advertisements, interviewer contacts, 
and snowballing (i.e., peer referral). Participants had to: i) be at least 16 years of age (due to ethical 
constraints), ii) have used ecstasy or other stimulants at least six times during the preceding six 
months; and iii) have been a resident of the capital city in which the interview took place for the past 
12 months. Interviews took place in varied locations negotiated with participants (e.g., research 
institutions, coffee shops or parks). Following provision of informed consent and completion of a 
structured interview, participants were reimbursed $40 for their time and expenses incurred. A total 
of 799 participants were recruited across capital cities nationally (April-July, 2019), with 100 
participants interviewed in Brisbane and the Gold Coast during April-May 2019. 
For normally distributed continuous variables, means and standard deviations (SD) are reported; for 
skewed data (i.e. skewness > ±1 or kurtosis > ±3), medians and interquartile ranges (IQR) are 
reported. Tests of statistical significance have been conducted between estimates for 2018 and 2019 
and are reported when significance reaches p<0.05; non-significant p-values are not reported. 
Note that no corrections for multiple comparisons have been made and thus comparisons should be 
treated with caution. Values where cell sizes are ≤5 have been suppressed with corresponding 
notation (null values are reported).  
Interpretation of Findings 
Caveats to interpretation of findings are discussed more completely in the methods for the annual 
interviews but it should be noted that these data are from participants recruited in Brisbane and the 
Gold Coast, and thus do not reflect trends in regional and remote areas. Further, the results are not 
representative of all people who consume illicit drugs, nor of illicit drug use in the general population, 
but rather intended to provide evidence indicative of emerging issues that warrant further monitoring.  
This report covers a subset of items asked of participants and does not include jurisdictional-level 
results beyond estimates of recent use of various substances (included in jurisdiction outputs; see 
below), nor does it include implications of findings. These findings should be interpreted alongside 
analyses of other data sources for a more complete profile of emerging trends in illicit drug use, market 
features, and harms in Queensland (see section on ‘Additional Outputs’ below for details of other 
outputs providing such profiles). 
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Additional Outputs 
Infographics from this report are available for download. There is a range of outputs from the EDRS 
which triangulate key findings from the annual interviews and other data sources, including 
jurisdictional reports, bulletins, and other resources available via the Drug Trends webpage. This 
includes results from Illicit Drug Reporting System (IDRS), which focuses more so on the use of illicit 
drugs, including injecting drug use. 
Please contact the research team at drugtrends@unsw.edu.au with any queries; to request additional 
analyses using these data; or to discuss the possibility of including items in future interviews. 
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1 
Sample Characteristics 
In 2019, the QLD sample was mostly male (66%) and had a median age of 20 (IQR=19-23). Forty-
three per cent reported having completed a post-school qualification(s) and 65% were currently 
studying. Renting was the most commonly reported form of accommodation (59%), followed by living 
in parents’/family home (34%) (Table 1).  
In 2019 cannabis was the most commonly reported drug of choice (28%; 27% in 2018), followed by 
ecstasy (23%), reversing the trend from 2018 when ecstasy was the most commonly reported (30%) 
drug of choice (Figure 1).  
Cannabis was the drug used most in the previous month (54%, compared to 41% in 2018), remaining 
the most commonly used drug since 2012. Alcohol was the second most used drug (21%, compared 
to 12% in 2018). The proportion of participants reporting ecstasy as the most used drug decreased 
significantly in 2019 to 15% (from 31% in 2018; p=0.007) (Figure 2). 
 
Figure 1: Drug of choice, Queensland, 2003-2019 
  
Note. Substances listed in this figure are the primary endorsed; nominal percentages have endorsed other substances. Y axis reduced to 
80% to improve visibility. Data labels have been removed from figures with small cell size (i.e. n≤5 but not 0). p<0.050; **p<0.010; ***p<0.001 
for 2018 versus 2019. 
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Table 1: Demographic characteristics of the sample, nationally and Queensland, 2015-2019 
 National 
2019 
QLD  
2019 
QLD 
2018 
QLD 
2017 
QLD 
2016 
QLD 
2015 
 N=797 N=100 N=100 N=100 N=92 N=85 
Median age (years; IQR) 
22 
(19-26) 
20 
(19-23) 
19 
(18-22) 
19 
(18-21) 
21 
(19-25) 
21 
(20-24) 
% Male 60 66 64 62 68 58 
% Aboriginal and/or Torres 
Strait Islander 5 5 3 4 4 1 
% Sexual identity       
Heterosexual 81 77 84 83 90 79 
Homosexual 5 - 5 3 - 9 
Bisexual 12 17 9 13 8 12 
Different identity - - 2 1 1 1 
Median years of school 
education  
12 
(8-12) 12 12 12 12 12 
% Post-school qualification(s)^ 54 43 29 25 38 46 
% Employment status       
Employed full-time 22 11 16 13 15 7 
Students# 45 65 42 49 64 63 
Unemployed 27 13 17 8 11 14 
Median weekly income $  500 
$360  
($250-550) 
$375  
($200-650) 
$300 
($200-550) 
$424  
($300-600) 
$350 
($250-
500) 
% Accommodation       
Own house/flat 4 - 1 3 5 9 
Rented house/flat 44 59 48 64 77 77 
Parents’/family home 48 34 47 26 12 9 
Boarding house/hostel 1 - 2 5 1 2 
No fixed address 2 0 1 2 4 2 
Other 1 0 1 - - - 
 
Note. ^Includes trade/technical and university qualifications. # Includes full-time students, part-time students and participants who both work 
and study. - Percentage suppressed due to small cell size (n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Figure 2: Drug used most often in the past month, Queensland,  2011-2019 
  
Note. Substances listed in this figure are the primary endorsed; nominal percentages have endorsed other substances. Data labels have 
been removed from figures with small cell size (i.e. n≤5 but not 0). Data are only presented for 2011-2019 as this question was not asked 
in 2003-2010. *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
 
Figure 3: Weekly or more frequent substance use in the past six months, Queensland,  2003-2019 
  
Note. Among the entire sample. Y axis reduced to 80% to improve visibility. Data labels have been removed from figures with small cell 
size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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2 
Ecstasy/MDMA 
 
Participants were asked about their recent (past six month) use of various forms of ecstasy (3,4-
methylenedoxymethamphetamine), including pills, capsules, crystal, and powder.  
Recent Use (past 6 months) 
In 2019, nearly all (99%) participants reported recent use of ecstasy, remaining stable from 2018 
(97%) and across all years of the study (Figure 4).  
Frequency of Use (past 6 months) 
The median days any ecstasy was used in 2019 was 14 (IQR=7-23), similar to 2018, where the 
median days used was 15 (IQR=8-23) (Figure 5, see following page). Nearly one-quarter (24%) of 
participants who had recently consumed ecstasy reported weekly or more use of any form of ecstasy, 
very similar to 2018 reports (23%). 
Figure 4: Past six month use of any ecstasy, and ecstasy pills, powder, capsules, and crystal, Queensland, 
2008-2019 
 
Note. Up until 2012, participant eligibility was determined based on any recent ecstasy use; subsequently it has been expanded to broader 
illicit stimulant use. Data collection for powder started in 2005, capsules in 2008 and crystal in 2013. Data labels have been removed from 
figures with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Figure 5: Median days of any ecstasy and ecstasy pills, powder, capsules, and crystal use in the past six 
months, Queensland, 2003-2019 
 
Note. Data collection for powder started in 2005, capsules in 2008 and crystal in 2013. Median days computed among those who reported 
recent use (maximum 180 days). Median days rounded to the nearest whole number. Y axis reduced to 30% to improve visibility of trends. 
Data labels have been removed from figures with small cell size (i.e. n≤5 but not 0).  *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Patterns of Consumption 
Ecstasy Pills 
Recent Use (past 6 months): Fifty-five per 
cent reported recently using pills; the lowest 
proportion recorded since data collection 
began. This is a significant decrease from 2018 
where 76% reported recent use of pills 
(p=0.002) (Figure 4).  
Frequency of Use (past 6 months): Median 
frequency declined to five days (IQR=2-12) 
from eight (IQR=3-13) in 2018 (Figure 5). Few 
participants (n≤5) reported weekly or more use. 
Routes of Administration: The most common 
ROA remained swallowing (96% versus 96% in 
2018), followed by snorting (27% versus 40% 
in 2018; p=0.011). Few reported recent 
shelving/shafting or smoking (n≤5).  
Quantity: The median number of pills used in 
a ‘typical’ session remained stable at two 
(IQR=2-3; n=55), while the median maximum 
amount used was four pills (IQR=2-6; n=55). 
Ecstasy Capsules 
Recent Use (past 6 months): Over three-
quarters (78%) reported recently using 
capsules, continuing a rising trend in QLD 
(72% in 2018) (Figure 4).  
Frequency of Use (past 6 months): Median 
frequency of use was eight days (IQR=7-23) in 
2019 compared to five days (IQR=3-14) in 
2018. The proportion using weekly or more 
remained low at 6% (low numbers in 2018 
suppressed; n≤5) (Figure 5). 
Routes of Administration: All participants 
who recently used capsules reported 
swallowing them (97% in 2018), while 18% 
also reported snorting them (14% in 2018). 
Quantity: The median number of capsules 
used in a ‘typical’ session remained stable at 
two (IQR=1.9-3.0), as did the median 
maximum amount (3 capsules; IQR=2-5).  
Ecstasy Crystal 
Recent Use (past 6 months): Sixty-five per 
cent of participants reported recently using 
crystal (66% in 2018) (Figure 4). 
Frequency of Use (past 6 months): Median 
frequency remained stable at six days (IQR=3-
10; 5 days in 2018 (IQR=2-10) (Figure 5). Few 
participants (n≤5) reported weekly or more use. 
Routes of Administration: Among those who 
had recently used crystal (n=65), swallowing 
was the most common ROA (85% versus 92% 
in 2018), followed by snorting (37% versus 
42% in 2018). A small number of participants 
reported shelving/shafting (6%). 
Quantity: The median amount of crystal used 
in a ‘typical’ session was stable at 0.2 grams 
(IQR=0.19-0.40; n=50). The median maximum 
amount used was 0.5 grams (IQR=0.3-1.0; 
n=52). 
Ecstasy Powder 
Recent Use (past 6 months): Recent use of 
ecstasy power was reported by 22% of 
participants (27% in 2018) (Figure 4). 
Frequency of Use (past 6 months): 
Frequency of use remained low at a median of 
three days (IQR=1-7; 3 days in 2018, IQR=2-
6) (Figure 5). 
Routes of Administration: The most common 
route of administration was snorting (64%; 74% 
in 2018) and swallowing (64%; 59% in 2018).  
Quantity: The median amount used in a 
‘typical’ session was 0.2 grams (IQR=0.2-0.4 
versus 0.5 grams in 2018 (IQR=0.2-0.6) and 
the median maximum amount used 0.4 grams 
(IQR=0.2-0.5 versus 0.8 grams in 2018 
(IQR=0.4-1.0).
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Market Trends 
Ecstasy Pills 
Price: The median price per pill of ecstasy was 
$20 (IQR=15-24; n=60), unchanged from 2018 
($20, IQR=12-20, n=79) (Figure 6).  
Perceived Purity: Among those who were 
able to comment in 2019 (n=59), 34% reported 
the strength of pills had ‘fluctuated’. One-
quarter (25%) perceived the purity of pills as 
‘medium’ (37% in 2018), 22% as ‘low’ (22% in 
2018) and 19% as ‘high’ (21% in 2018) (Table 
2). 
Perceived Availability: Among those who 
were able to comment in 2019 (n=60), 85% of 
participants reported that it was ‘very easy’ or 
‘easy’ to obtain pills, compared to 94% in 2018 
(p=0.042) (Table 2).  
Ecstasy Capsules 
Price: The reported median price of an ecstasy 
capsule was $20 in 2019 (IQR=15-25; n=74), 
unchanged from 2018 ($20, IQR=15-20; n=76) 
(Figure 6). 
Perceived Purity: Among those who were 
able to comment in 2019 (n=77), most 
participants perceived purity as ‘high’ (38%) 
and ‘medium’ (34%); unchanged from 2018 
(38% ‘high’, 34% ‘medium’) (Table 2). 
Perceived Availability: Among those who 
were able to comment in 2019 (n=77), 91% of 
participants reported that it was ‘very easy’ or 
‘easy’ to obtain capsules, an increase from 
83% in 2018 (p=0.028) (Table 2).   
 
Ecstasy Crystal 
Price: The median price for a gram of crystal 
was $130 in 2019 (IQR=100-185; n=29), 
similar to $160 in 2018 (IQR=100-210; n=29) 
(Figure 7). 
Perceived Purity: Among those who were 
able to comment in 2019 (n=55), over three-
quarters perceived purity as ‘high’ (76%; 54% 
in 2018; p=0.024), followed by ‘medium’ (16%; 
34% in 2018, p=0.032) (Table 2). 
Perceived Availability: Among those who 
were able to comment in 2019 (n=56), 70% 
reported ecstasy crystal as ‘very easy’ or ‘easy’ 
to obtain (75% in 2018) (Table 2). 
Ecstasy Powder 
Price: The reported median price per gram of 
ecstasy powder was $150 (IQR=50-200; n=7). 
Perceived Purity: Among those who were 
able to comment in 2019 (n=9), one-third 
perceived the purity of powder to be ‘high’ or 
‘medium’ (33% for each).  
Perceived Availability: Among those who 
were able to comment in 2019 (n=9), two-thirds 
perceived powder to be ‘very easy’ or ‘easy’ 
(67%) to obtain.  
Comparisons with 2018 are not reported for 
ecstasy powder due to low numbers who 
reported on price, perceived purity and 
perceived availability.   
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Figure 6: Median price of ecstasy pill and capsule, Queensland, 2003-2019 
 
Note. Among those who commented. Data collection for price of ecstasy capsules started in 2008. Data labels have been removed from 
figures with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
 
Figure 7: Median price of ecstasy crystal per point and gram, Queensland, 2014-2019 
 
Note. Among those who commented. Data collection for price of ecstasy crystal gram and point started in 2013 and 2014, respectively. 
Data not presented for 2013 due to only two participants reporting purchasing crystal. Data labels have been removed from figures with 
small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Table 2: Perceived purity and availability of ecstasy pills, capsules and crystal, Queensland,  2016-2019 
 2016 2017 2018 2019 
Current Perceived Purity     
% Pills (n)# (n=74) (n=79) (n=81) (n=59) 
Low 11 14 22 22 
Medium 38 50 37 25 
High 31 13 21 19 
Fluctuates 10 23 20 34 
% Capsules (n) # (n=79) (n=76) (n=77) 
Low # 8 13 5 
Medium # 39 34 34 
High # 42 38 38 
Fluctuates # 12 15 23 
% Crystal (n) (n=50) (n=62) (n=50) (n=55) 
Low - 5 4 - 
Medium 20 35 34 16 
High 68 45 54 76 
Fluctuates 10 16 8 - 
Current Perceived Availability     
% Pills (n) # (n=78) (n=79) (n=80) (n=60) 
Very easy 54 51 61 42 
Easy 42 42 33 43 
Difficult - 8 6 10 
Very difficult 0 - - 5 
% Capsules (n) # (n=78) (n=76) (n=77) 
Very easy # 45 30 53 
Easy # 42 23 38 
Difficult # 12 16 9 
Very difficult # 1 1 0 
% Crystal (n) (n=50) (n=63) (n=48) (n=56) 
Very easy 38 33 23 29 
Easy 44 43 52 41 
Difficult 18 22 25 29 
Very difficult 0 2 - - 
Note. The response option ‘Don’t know’ was excluded from analysis. #In 2016, pills, powder and capsules were asked together. - Percentage 
suppressed due to small cell size (n≤5 but not 0). Data regarding purity and availability of ecstasy powder not reported due to low numbers 
(n≤5 but not 0) *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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3 
Methamphetamine 
 
Participants were asked about their recent (past six months) use of various forms of 
methamphetamine, including powder (white particles, described as speed), base (wet, oily powder) 
and crystal (clear, ice-like crystals).  
Recent Use (past 6 months) 
Recent use of any methamphetamine has been declining since monitoring began; two-thirds (67%) 
of participants recently used any methamphetamine in 2003 versus 24% who had recently used 
methamphetamine in 2019 (Figure 8).   
Frequency of Use (past 6 months) 
Frequency of use over time has been variable with no clear trends (Figure 9).  
Figure 8: Past six month use of any methamphetamine, powder, base, and crystal, Queensland, 2003-
2019 
 
Note. Data labels have been removed from figures in years of initial monitoring, and 2018 and 2019 with small cell size (i.e. n≤5 but not 0). 
*p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Figure 9: Median days of any methamphetamine, powder, base, and crystal use in the past six months, 
Queensland, 2003-2019 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Y axis reduced to 14 days to improve visibility of trends. Data labels have been removed from figures in years of initial monitoring, 
and 2018 and 2019 with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Patterns of Consumption 
Crystal Methamphetamine 
Recent Use (past 6 months): Sixteen per cent 
of the total sample had used crystal in the six 
months preceding interview (12% in 2018) 
showing an increasing trend since 2017 
(Figure 8). 
Frequency of Use (past 6 months): Median 
days of use in 2019 was five days (IQR=2-25), 
similar to 2018 (4 days, IQR=2-9) (Figure 9). A 
small number of participants (n≤5) used crystal 
weekly or more. 
Routes of Administration: Among those who 
had used crystal in the last six months (n=16), 
most participants (81%) reported smoking 
(75% in 2018), followed by swallowing (31% 
versus 25% in 2018). Low numbers reported 
snorting or injecting (n≤5).  
Quantity: The median amount used in a 
‘typical’ session was two points (IQR=1-3; 
n=10; 1 point in 2018; n=7) (≤5 participants 
reported quantity in grams; data suppressed).  
The largest amount used in a session was a 
median of four points (IQR=2-5; n=8) or one 
gram (IQR=1-3; n=7). 
Methamphetamine Powder  
Recent Use (past 6 months): The proportion 
of participants who had used speed in the last 
six months remained relatively stable at 9%, 
compared to 10% in 2018 (Figure 8). 
Frequency of Use (past 6 months): Median 
days used in 2019 was one (IQR=1.0-3.5), not 
significantly different to four days (IQR=2-8) in 
2018 (Figure 9). 
Routes of Administration: The most common 
ROA among those who had used speed (n=9) 
was snorting (67%; ≤5 participants reported 
other ROAs; data are suppressed). This was in 
contrast to 2018 reports, where 70% of 
participants reported swallowing and 40% 
reported snorting. 
Quantity: Five or fewer participants reported 
quantity in points or grams; these data are 
suppressed.  
Methamphetamine Base  
Due to low numbers, details will not be reported 
on base. For further information, please refer 
to the National Report, or contact the Drug 
Trends team.  
Market Trends 
Crystal Methamphetamine 
Price: Median price per point in 2019 remained 
stable at $50 (IQR=35-50; n=9), and increased 
slightly though non-significantly to $275 per 
gram (IQR=250-300; n=6; ≤5 participants 
reported in 2018; these data are suppressed) 
(Figure 10). 
Perceived Purity: Among those who were 
able to comment in 2019 (n=14), 93% 
perceived crystal to be ‘high’ in purity, 
compared to 2018 (n=11), where 55% 
perceived purity as ‘high’ (p=0.020) (Figure 
11). 
Perceived Availability: Among those who 
were able to comment in 2019 (n=14), 93% 
perceived it was ‘very easy’ or ‘easy’ to obtain 
crystal, compared to 82% in 2018 (Figure 12). 
Methamphetamine Powder and 
Methamphetamine Base 
Due to low numbers, details will not be reported 
on methamphetamine powder or 
methamphetamine base. For further 
information, please refer to the National 
Report, or contact the Drug Trends team.  
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Figure 10: Median price of crystal methamphetamine per point and gram, Queensland, 2003-2019 
 
Note. Among those who commented. Data labels have been removed from figures with small cell size (i.e. n≤5 but not 0). *p<0.050; 
**p<0.010; ***p<0.001 for 2018 versus 2019. 
 
Figure 11: Current perceived purity of crystal methamphetamine, Queensland, 2003-2019 
 
Note. The response ‘Don’t know’ was excluded from analysis. Data not presented for years where n<10 (2010 & 2013). Data labels have 
been removed from figures with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Figure 12: Current perceived availability of crystal methamphetamine, Queensland, 2003-2019 
 
Note. The response ‘Don’t know’ was excluded from analysis. Data not presented for years where n<10 (2010 and 2013). Data labels have 
been removed from figures with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
 
 
Figure 13: Median price of powder methamphetamine per point and gram, Queensland, 2003-2019 
 
Note. Among those who commented. Data not presented for years with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 
for 2018 versus 2019. 
 
Figures for perceived purity and availability for powder methamphetamine are not presented due to 
numerous years with low numbers of respondents (n<10). For further information, please refer to the 
National Report, or contact the Drug Trends team.  
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4 
Cocaine 
 
Participants were asked about their recent (past six month) use of various forms of cocaine.  Cocaine 
hydrochloride, a salt derived from the coca plant, is the most common form of cocaine available in 
Australia. ‘Crack’ cocaine is a form of freebase cocaine (hydrochloride removed), which is particularly 
pure. ‘Crack’ is most prevalent in North America and infrequently encountered in Australia. 
Patterns of Consumption 
Recent Use (past 6 months) 
Two-thirds (67%) of the total sample had recently used cocaine, continuing an increasing trend in 
Queensland. This was a non-significant increase from 60% in 2018 (Figure 14).  
Frequency of Use (past 6 months) 
The median number of days used in the last six months remained stable at three (IQR=2-6) (Figure 
14).  
Routes of Administration 
The most common ROA among participants who had recently used cocaine (n=67) was snorting 
(97%), with a small percentage also swallowing (12%) cocaine in the last six months. This was similar 
to the pattern reported in 2018, with 98% snorting and 10% swallowing. 
Quantity 
The median amount of cocaine used in a ‘typical’ session was 0.5 grams (IQR=0.5-0.5; n=39) or two 
points (IQR=2-3.5.0; n=12).  
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Figure 14: Past six month use and frequency of use of cocaine, Queensland, 2003-2019 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Y axis reduced to 6 days to improve visibility of trends. Data labels have been removed from figures in initial years of monitoring, 
2018 and 2019 with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
 
Market Trends  
Price  
In 2019, the median price per gram of cocaine remained stable at $300 (IQR=300-350; n=45) (Figure 
15).  
Perceived Purity 
Among those who were able to comment in 2019 (n=50), 30% perceived purity as ‘high’ (24% in 
2018), 36% as ‘medium’ (36% in 2018) and 26% as ‘low’ (29% in 2018) (Figure 16).  
Perceived Availability 
Among those who were able to comment in 2019 (n=53), 59% reported that it was ‘easy’ or ‘very 
easy’ to obtain cocaine, while the remainder (41%) reported that it was ‘difficult’ or ‘very difficult’. 
Reports were similar in 2018, where 60% of participants perceived cocaine as being ‘easy’ or ‘very 
easy’ to obtain (Figure 17). 
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Figure 15: Median price of cocaine per gram, Queensland, 2003-2019 
  
Note. Among those who commented. Data labels have been removed from figures with small cell size (i.e. n≤5 but not 0). *p<0.050; 
**p<0.010; ***p<0.001 for 2018 versus 2019. 
Figure 16: Current perceived purity of cocaine, Queensland, 2003-2019 
 
Note. The response ‘Don’t know’ was excluded from analysis. Data labels have been removed from figures with small cell size (i.e. n≤5 but 
not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Figure 17: Current perceived availability of cocaine, Queensland, 2003-2019 
 
Note. The response ‘Don’t know’ was excluded from analysis. Data labels have been removed from figures with small cell size (i.e. n≤5 but 
not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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5 
Cannabis 
 
Participants were asked about their recent (past six month) use of indoor-cultivated cannabis via a 
hydroponic system (‘hydro’) and outdoor-cultivated cannabis (‘bush’), as well as hashish and hash 
oil.  
Patterns of Consumption 
Recent Use (past 6 months)  
Ninety-two per cent of participants reported recent use of cannabis. The proportion reporting recent 
use in 2019 was similar to that of 2018 (95%) (Figure 18).  
Frequency of Use (past 6 months) 
The median number of days used in 2019 was 90 (IQR=22.5-180.0), a non-significant increase from 
60 days (IQR=12-170) in 2018 (p=0.123). Over one-quarter (27%) of participants who had recently 
used cannabis reported using it daily in 2019 (20% in 2018) (Figure 18).    
Routes of Administration 
The most common ROA in 2019 was smoking (96%), while substantial proportions also reported 
inhaling/vaporising (29%) and swallowing (22%). In 2018, 100% reported smoking, 21% 
inhaling/vaporising and 18% swallowing.  
Quantity 
The median amount used in a ‘typical’ session was one gram (IQR=0.5-2.0; n=37; 1.5 grams in 2018; 
IQR=0.8-3.5; n=19, p=0.572) or 3.5 cones (IQR=2-6; n=36; 3 cones in 2018; IQR=2-6; n=54).  
Forms Used 
Among participants who had recently used cannabis (n=92), 82% had recently used hydroponic 
cannabis; 75% had recently used bush cannabis; 21% had recently used hashish; and 23% had 
recently used hash oil. The form that was used most in the last 6 months was hydroponic (65%), 
followed by bush (33%). 
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Figure 18: Past six month use and frequency of use of cannabis, Queensland, 2003-2019 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Y axis reduced to 90 days to improve visibility of trends. Data labels have been removed from figures in years of initial monitoring, 
2018 and 2019 with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
 
Market Trends 
Hydroponic Cannabis 
Price: The median price per gram in 2019 remained stable at $15 (IQR=10.75-20.00; n=17), as did 
the price per ounce at $270 (IQR=250-300; n=33 versus $250 in 2018, IQR=245-290; n=36) (Figure 
19). 
Perceived Potency: Among those who were able to comment in 2019 (n=64), 34% perceived 
potency as ‘high’, 36% as  ‘medium’, and 22% as ‘low’; compared to 2018 where 35% perceived purity 
as ‘high’, 41% as ‘medium’, and 12% as ‘low’ (Figure 20).  
Perceived Availability: Among those who were able to comment in 2019 (n=65), 88% of participants 
perceived hydroponic cannabis as ‘very easy’ or ‘easy’ to obtain, with the remaining 12% perceiving 
it as ‘difficult’ or ‘very difficult’ to obtain. This was similar to 2018 reports, where 86% perceived it as 
‘very easy’ or ‘easy’ to obtain and 14% as ‘difficult’ or ‘very difficult’ (Figure 21).   
Bush Cannabis 
Price: The median price per gram in 2019 was $15 (IQR=10.0-17.5; n=17 versus $13 in 2018, 
IQR=10-10; n=20; p=0.790); or $250 per ounce (IQR=235-300; n=25, stable from 2018) (Figure 19).   
Perceived Potency: Among those who were able to comment in 2019 (n=58), 41% perceived 
potency as ‘high’, 38% as ‘medium’, and 14% as ‘low’; compared to 2018 where 26% perceived 
potency as ‘high’, 55% as ‘medium’, and 17% as ‘low’ (Figure 20).  
Perceived Availability: Among those who were able to comment in 2019 (n=59), 64% of participants 
perceived bush cannabis as ‘very easy’ or ‘easy’ to obtain, with the remaining 36% perceiving it as 
‘difficult’ or ‘very difficult’. This was similar to 2018, where 67% perceived it as ‘very easy’ or ‘easy’ to 
obtain and 33% as ‘difficult’ or ‘very difficult’ (Figure 21). 
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Figure 19: Median price of hydroponic (A) and bush (B) cannabis per ounce and gram, Queensland, 2006-
2019 
 
(A) Hydroponic cannabis 
 
 
(B) Bush cannabis 
 
Note. From 2006 onwards hydroponic and bush cannabis data collected separately. Data labels have been removed from figures in years 
of initial monitoring, and 2018 and 2019 with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Figure 20: Current perceived potency of hydroponic (A) and bush (B) cannabis, Queensland, 2006-2019 
 
(A) Hydroponic cannabis 
 
 
(B) Bush cannabis 
 
Note. The response ‘Don’t know’ was excluded from analysis. From 2006 onwards, hydroponic and bush cannabis data collected separately. 
Data labels have been removed from figures with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Figure 21: Current perceived availability of hydroponic (A) and bush (B) cannabis, Queensland, 2006-2019 
 
(A) Hydroponic cannabis 
 
 
(B) Bush cannabis 
 
Note. The response ‘Don’t know’ was excluded from analysis. From 2006 onwards, hydroponic and bush cannabis data collected separately. 
Data labels have been removed from figures with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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6 
Ketamine, LSD, and Hallucinogenic Mushrooms 
Ketamine 
Patterns of Consumption 
Recent Use (past 6 months): Twenty-seven per cent of the total sample had recently used ketamine, 
remaining stable from 2018 whereby 28% had recently used the drug (Figure 22). 
Frequency of Use (past 6 months): The median days used in 2019 was three (IQR=1-6), unchanged 
from three days in 2018 (IQR=1-4) (Figure 22).  
Routes of Administration: The most commonly reported ROA in 2019 was snorting (85% versus 
86% in 2018), followed by swallowing (19% versus 25% in 2018). A small number of participants (n≤5) 
reported smoking ketamine in 2019. 
Quantity: The median amount of ketamine used in a ‘typical’ session in 2019 was 0.2 grams 
(IQR=0.15-0.50; n=19). 
Figure 22: Past six month use and frequency of use of ketamine, Queensland, 2003-2019 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Y axis reduced to 50% and 4 days to improve visibility of trends. Data labels have been removed from figures with small cell size 
(i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Market Trends 
Price: The median price per gram in 2019 was $200 (IQR=112.5-207.5; n=12), compared to $175 in 
2018; IQR=140-220; n=10). In previous years, the number of reports was too small to include (n≤5). 
Perceived Purity: Among those who were able to comment in 2019 (n=19), most perceived the purity 
of ketamine as ‘high’ (74%) and 16% perceived it as ‘medium’, compared to 2018 where 64% 
perceived the purity as ‘high’ and 36% as ‘medium’. Prior to 2016, the number of reports was too 
small to include (n≤5). 
Perceived Availability: Among those who were able to comment in 2019 (n=21), 43% reported 
ketamine as ‘very easy’ or ‘easy’ to obtain, while 67% reported it as ‘difficult’ or ‘very difficult’; 
compared to 2018 where 64% reported that it was ‘very easy’ or ‘easy’ to obtain. In years previous to 
2016, the number of reports was too small to include (n≤5). 
LSD 
Patterns of Consumption 
Recent Use (past 6 months): Fifty-three per cent of participants reported recently using LSD, a 
decrease from 61% in 2018 (p=0.253), but overall maintaining the trend of increased use compared 
to the early years of data collection (Figure 23). 
Frequency of Use: The median days used in the last six months was two (IQR=2-5), compared to 
three days in 2018 (IQR=1-7; p=0.627) (Figure 23).   
Routes of Administration: All participants who reported using LSD in 2019 did so by swallowing 
(98% in 2018). 
Quantity: In 2019, the median amount used in a ‘typical’ session was one tab (IQR=1-2; n=34), or 
220 micrograms (IQR=135-312; n=18). 
Figure 23: Past six month use and frequency of use of LSD, Queensland, 2003-2019 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Y axis reduced to 70% and 5 days to improve visibility of trends. Data labels have been removed from figures with small cell size 
(i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Market Trends 
Price: In 2019, the median price per tab was $20 (IQR=15-25; n=58); stable from previous years 
(Figure 24). 
Perceived Purity: Among those who were able to comment in 2019 (n=58), 47% perceived the purity 
of LSD as ‘high’ (55% in 2018) and 29% as ‘medium’ (35% in 2018) (Figure 25). 
Perceived Availability: Among those who were able to comment in 2019 (n=60), 45% of participants 
reported that it was ‘very easy’ or ‘easy’ to obtain LSD, while 55% reported that it was ‘difficult’ or 
‘very difficult’ to obtain. In 2018 (n=60), 60% reported that it was ‘very easy’ or ‘easy’ to obtain LSD, 
while 40% reported that it was ‘difficult’ or ‘very difficult’ to obtain (Figure 26). 
Figure 24: Median price of LSD per tab, Queensland, 2003-2019 
 
Note. Among those who commented. Data labels have been removed from figures with small cell size (i.e. n≤5 but not 0). *p<0.050; 
**p<0.010; ***p<0.001 for 2018 versus 2019. 
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Figure 25: Current perceived purity of LSD, Queensland, 2003-2019 
  
Note. The response ‘Don’t know’ was excluded from analysis. Data labels have been removed from figures with small cell size (i.e. n≤5 but 
not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
Figure 26: Current perceived availability of LSD, Queensland, 2003-2019 
 
Note. The response ‘Don’t know’ was excluded from analysis. Data labels have been removed from figures with small cell size (i.e. n≤5 but 
not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
 
Hallucinogenic Mushrooms 
Patterns of Consumption 
Recent Use (past 6 months):  Twenty-eight per cent of participants reported recently using 
mushrooms, similar to 2018 (27%; p=0.874) and remaining fairly stable since 2014 (Figure 27).    
Frequency of Use (past 6 months): The median number of days used in the last six months was 
one day (IQR=1-3), compared to two days in 2018 (IQR=1-3; p=0.928) (Figure 27). 
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Figure 27: Past six month use and frequency of use of mushrooms, Queensland, 2005-2019 
 
Note. Median days computed among those who reported recent use (maximum 180 days). Median days rounded to the nearest whole 
number. Y axis reduced to 5 days to improve visibility of trends. Data labels have been removed from figures with small cell size (i.e. n≤5 
but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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7 
New Psychoactive Substances 
 
NPS are often defined as substances which do not fall under international drug control, but which may 
pose a public health threat. However, there is no universally accepted definition, and in practicality 
the term has come to include drugs which have previously not been well-established in recreational 
drug markets. 
In 2019, 33% of participants reported recent use of any NPS, not significantly higher than the 29% 
reported in 2018.  
Consistent with past years, the most common NPS was DMT (16% versus 16% in 2018) which was 
used on a median of one day in the past six months (IQR=1-2; n=16), followed by 2C-B (10% versus 
13% in 2018). The proportion of participants reporting recent use of other NPS was low (n≤5) and 
therefore these numbers have been suppressed (Figure 28).  
EDRS collects data on a large number of NPS specifically by name, however those with negligible 
numbers of participants reporting recent use are not included here. If further details about use of other 
NPS by the Queensland EDRS participants are needed, please contact the Drug Trends team, or 
refer to the National Report for national trends in use.  
Figure 28: Any use of NPS, Queensland, 2012-2019 
 
Note. Y axis reduced to 70% to improve visibility of trends. Data labels have been removed from figures with small cell size (i.e. n≤5 but not 
0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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8 
Other Drugs 
 
Non-Prescribed Pharmaceutical Drugs 
Codeine 
Before the 1st February 2018, people could access low-dose codeine products (<30mg, e.g., Nurofen 
Plus) over-the-counter (OTC), while high-dose codeine (≥30mg, e.g., Panadeine Forte) required a 
prescription from a doctor. On the 1st February 2018, legislation changed so that all codeine products, 
low- and high-dose, require a prescription from a doctor to access. 
Up until 2017, participants were only asked about use of OTC codeine for non-pain purposes. 
Additional items on use of prescription low-dose and prescription high-dose codeine were included in 
IDRS 2018 and 2019. 
Recent Use (past 6 months): In 2019, 33% of the sample reported any recent use of codeine (42% 
in 2018). Nineteen per cent of the sample had used prescribed codeine, whereas 14% reported using 
non-prescribed codeine.  
Recent Use for Non-Pain Purposes: Seven per cent of participants reported using low dose codeine 
for non-pain purposes, compared to 11% who did so in 2018. 
Frequency of Use (past 6 months):  The median number of days of any codeine use in 2019 in the 
last six months was three (IQR=2-7), remaining stable from 2018 (IQR=2-15).  
Forms Used: In 2019, 18% of participants had used low dose codeine (9% used non-prescribed low-
dose codeine) and 15% had used high dose codeine (very small numbers reported recent use of non-
prescribed high-dose codeine (n≤5) and therefore data have been suppressed). 
Pharmaceutical Opioids 
Recent Use (past 6 months): Past six month use of non-prescribed pharmaceutical opioids (e.g. 
morphine, oxycodone, excluding codeine) was reported by 17% of participants in 2019, similar to 19% 
in 2018 (Figure 29). 
Frequency of Use (past 6 months): Median number of days of pharmaceutical opioid use in 2019 
was three (IQR=2-5; n=17; 2 days in 2018, IQR=2-5; n=19). 
Pharmaceutical Stimulants 
Recent Use (past 6 months): Non-prescribed pharmaceutical stimulant (e.g. dexamphetamine, 
methylphenidate, modafinil) use was reported by 39% of participants, continuing a downward trend 
since 2016 (58%), but remaining much higher than when data collection began in 2007 (11%) (Figure 
29). 
Frequency of Use (past 6 months): Frequency of use in 2019 was a median of four days (IQR=2-
10), remaining stable from 2018 (IQR=2-8; p=0.902). 
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Benzodiazepines 
Recent Use (past 6 months): Fifty per cent of participants had recently used non-prescribed 
benzodiazepines; similar to 2018 (56%, p=0.322) but continuing an overall increase since data 
collection began in 2007 (20%). In 2019, we asked participants for the first time about non-prescribed 
alprazolam use versus other non-prescribed benzodiazepine use, with 42% and 30% of the total 
sample reporting recent non-prescribed use, respectively (Figure 29). 
Frequency of Use (past 6 months): Consumers reported a median of three days for Alprazolam 
(IQR=1-10) and three days for ‘other benzodiazepines’ (IQR=2-10), compared to five days for any 
benzodiazepines in 2018 (IQR=3-10).  
Antipsychotics 
Recent Use (past 6 months): Non-prescribed antipsychotics were used by 13% of participants, 
compared to 7% in 2018 (p=0.157) (Figure 29). 
Frequency of Use (past 6 months): The median number of days used in the last six months was 
two (IQR=1-12) in 2019 and one (IQR=1=3) in 2018 (p=0.948).  
Other Illicit Drugs 
MDA 
Recent Use (past 6 months): One-tenth (10%) of participants had recently used MDA, compared to 
20% in 2018 (p=0.072) (Figure 30). 
Frequency of Use (past 6 months): The median number of days used was two (IQR=1-6), 
unchanged from 2018 (IQR=1.0-4.5).  
Substance with Unknown Contents  
Capsules: Thirteen per cent of participants reported recent use of capsules with unknown contents 
in 2019 (12% in 2018; p=0.831). Capsules with unknown contents were used on a median of two days 
in 2019 (IQR=1.0-5.5), compared to one day in 2018 (IQR=1-1) (Figure 30). 
Other Unknown Substances: In 2019, we asked participants about their use more broadly of 
substances with ‘unknown contents’. These questions were asked by substance form, comprising 
capsules (as per previous years), pills, powder, crystal and ‘other’ form. Twenty-eight per cent 
reported use of any substance with ‘unknown contents’ in 2019 and 18% of participants reported 
using pills with unknown contents in the previous six months on a median of two days (IQR=1-3). Very 
small numbers reported use of unknown powder or crystal (n≤5). 
GHB/GBL 
Very small numbers reported recent use of GHB/GBL and therefore data are not described.  If further 
details about the use of GHB/GBL by the QLD EDRS sample are needed, please contact the Drug 
Trends team, or refer to the National Report for national trends in use (Figure 30). 
Heroin 
Very small numbers reported recent use of heroin and therefore data are not described.  If further 
details about the use of heroin are needed, please contact the Drug Trends team, or refer to the 
National Report for national trends in use (Figure 30). 
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Licit and Other Drugs 
Alcohol 
Recent Use (past 6 months): All participants reported using alcohol in the past six months in 2019 
(99% in 2018) (Figure 31). 
Frequency of Use (past 6 months): The median number of days used was 38 (IQR=20-52), not 
significantly different from the 24 days reported in 2018 (IQR=12-58). Nearly three quarters (72%) of 
recent consumers drank alcohol weekly or more (similar to 64% in 2018). In 2019, 60% of recent 
consumers drank five or more standard drinks the last time they consumed a psychostimulant drug, 
a marginally significant increase from 47% in 2018. 
Tobacco 
Recent Use (past 6 months): Recent tobacco use continued an increasing trend since 2014, 
although changes from 2018 were not significant. The majority (87%) of the sample reported recent 
use in 2019 (85% in 2018) (Figure 31).  
Frequency of Use (past 6 months): Recent consumers reported using tobacco on a median of 90 
days (IQR=20-180), remaining stable from 2018 (also 90 days, IQR=20-180; n=85). Forty per cent of 
participants who had recently consumed tobacco reported daily use in 2019 (34% in 2018). 
E-cigarettes 
Recent Use (past 6 months): Fifty per cent of the sample reported recent use in 2019, compared to 
26% in 2018 (p<0.001) (Figure 31). 
Frequency of Use (past 6 months): Median days used in the last six months was seven (IQR=3-
20), compared to five days in 2018 (IQR=2-10). 
Forms Used: Among those who had recently used e-cigarettes (n=50), 82% reported that they 
contained nicotine (88% in 2018; n=26), and 14% were using e-cigarettes as a smoking cessation 
tool (27% in 2018).  
Nitrous Oxide 
Recent Use (past 6 months): Recent use of nitrous oxide remained steady with 56% of the sample 
reporting recent use in 2019 (57% 2018) (Figure 31).  
Frequency of Use (past 6 months): Recent consumers reported using nitrous oxide on a median of 
five days (IQR=2-10) (6 days in 2018).  
Quantity: The median amount used in a ‘typical’ session in 2019 was five bulbs (IQR=3-10), 
compared to eight bulbs in 2018 (IQR=4-12).  
Amyl Nitrite 
Amyl nitrite is an inhalant which is currently listed as Schedule 4 substance in Australia (i.e. available 
only with prescription) yet is often sold under-the-counter in sex shops. Following a review by the 
Therapeutic Goods Administration, amyl nitrite will be listed as Schedule 3 (i.e., for purchase over-
the-counter) from 1 February 2020 when sold for human therapeutic purpose. 
Recent Use (past 6 months): Two-fifths (40%) of participants reported recent use of amyl nitrite in 
2019, increasing from 22% in 2018 (p=0.005) (Figure 31). 
Frequency of Use (past 6 months): The median frequency of use was two days (IQR=2-7), 
compared to four days in 2018 (IQR=2-10). 
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Figure 29: Non-prescribed use of pharmaceutical drugs in the past six months, Queensland, 2007-2019 
 
Note. Non-prescribed use is reported for prescription medicines (i.e., benzodiazepines, antipsychotics, and pharmaceutical stimulants). In 
February 2018, the scheduling for codeine changed such that low-dose codeine formerly available over-the-counter (OTC) was required to 
be obtained via a prescription. Note that estimates of codeine OTC use refer to use for non-pain purposes. Y axis reduced to 60% to 
improve visibility of trends. Data labels have been removed from figures with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; 
***p<0.001 for 2018 versus 2019. 
 
Figure 30: Other illicit drugs used in the past six months, Queensland, 2003-2019 
 
Note. Monitoring of capsules contents unknown commenced in 2013. Y axis has been reduced to 50% to improve visibility of trends. Data 
labels have been removed from figures with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Figure 31: Licit drugs used in the past six months, Queensland, 2003-2019 
 
Note. Monitoring of e-cigarettes commenced in 2014. Data labels have been removed from figures with small cell size (i.e. n≤5 but not 0). 
*p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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9 
Drug-Related Harms and Other Risk Factors 
 
Polysubstance Use  
Nearly all (94%) participants reported using other substances on their last occasion of stimulant use 
(99% in 2018). The drugs most commonly used in conjunction with last stimulant use were alcohol 
(79%; 60% ≥5 standard drinks), cannabis (58%) and tobacco (41%).  
Ninety-one per cent of participants reported using depressants, cannabis, and/or 
hallucinogens/dissociatives on their last occasion of stimulant use, with the most common 
combination being stimulants, depressants and cannabis (41%) (Figure 32).  
In 2019, 30% of participants reported using stimulants or related drugs for 48 hours or more without 
sleep, compared to 37% in 2018 (p=0.294). 
Figure 32: Polysubtance use on occasion of last stimulant use, Queensland, 2019 
 
Note. This figure captures those who had also used hallucinogens/dissociatives (GHB, ketamine, LSD, and/or hallucinogenic mushrooms), 
depressants (alcohol and/or benzodiazepines) and/or cannabis on their last occasion of stimulant use (94% of the sample). No participants 
reported using hallucinogens and dissociatives only in addition to stimulants. 
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Harmful Consumption of Alcohol 
The Alcohol Use Disorders Identification Test (AUDIT) was designed by the World Health 
Organisation (WHO) as a brief screening scale to identify individuals with alcohol problems, including 
those in early stages. The mean score on the AUDIT for the Queensland EDRS sample was 14 
(SD=7), indicating that, on average, participants consumed alcohol at a hazardous level in the past 
year. In 2019, 83% of participants obtained a score of 8 or more, indicative of hazardous alcohol use 
(Table 3), compared to 68% in 2018 (p=0.020). AUDIT scores are divided into four ‘zones’ which 
indicate risk level (Table 3). 
 
Table 3: AUDIT total scores and per cent of participants scoring above recommended levels, Queensland, 
2014-2019 
 2014 
(n=100) 
2015 
(n=85) 
2016 
(n=92) 
2017 
(n=100) 
2018 
(n=100) 
2019 
(n=100) 
Mean AUDIT total score (SD) 13 (8) 14 (7) 12 (7) 13 (7) 11 (7) 14 (7) 
Score 8 or above (%) 78% 78% 71% 76% 68% 83%* 
Zone 1 (low risk drinking or abstinence) 22 21 29 24 31 17 
Zone 2 (alcohol in excess of low-risk guidelines) 46 36 37 43 42 44 
Zone 3 (harmful or hazardous drinking) 16 15 16 12 13 19 
Zone 4 (possible alcohol dependence) 16 27 17 21 13 20 
Note. *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
Non-Fatal Overdose 
Previously, participants had been asked about their experience in the past 12-months of i) stimulant 
overdose, and ii) depressant overdose.  
 
In 2019, changes were made to this module. Participants were asked about the following, prompted 
by the definitions provided:  
 
• Alcohol overdose: experience of symptoms (e.g., reduced level of consciousness, 
respiratory depression, turning blue and collapsing) where professional assistance would have 
been helpful.  
• Opioid overdose: same definition as above.  
• Stimulant overdose: experience of symptoms (e.g., nausea, vomiting, chest pain, tremors, 
increased body temperature, increased heart rate, seizure, extreme paranoia, extreme 
anxiety, panic, extreme agitation, hallucinations, excited delirium) where professional 
assistance would have been helpful.  
• Other drug overdose: similar definition to above.  
 
It is important to note that events reported on for each drug type may not be unique given high rates 
of polysubstance use.  
 
For the purpose of comparison with previous years, we computed the per cent reporting any 
depressant overdose, comprising any endorsement of alcohol or opioid overdose or other drug 
overdose where a depressant (e.g. GHB, benzodiazepines) was listed.  
 
Non-Fatal Depressant Overdose 
Alcohol: Over one-third (35%) of QLD participants reported experiencing an adverse event while 
using alcohol on a median of two occasions (IQR=1-3). Of those who had experienced an adverse 
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event while using alcohol, 86% reported not receiving treatment and only a small number reported 
receiving treatment (n≤5).  
Any Depressant (including alcohol): Past 12-month experience of non-fatal depressant overdose 
appeared to increase substantially from 8% in 2018 to 39% in 2019 (but we note that changes in how 
items regarding overdose and adverse event were asked in 2019 may have confounded these data). 
Amongst those who reported experiencing an adverse event while using a depressant drug (n=39), 
most reported an alcohol-related event (n=35; 2018 numbers ≤5 and suppressed), with smaller 
numbers reporting opioids, benzodiazepines and alprazolam (n≤5 and suppressed) (Figure 33).    
Non-Fatal Stimulant Overdose 
In 2019, 22% of participants reported that they had experienced a non-fatal stimulant overdose in the 
previous 12 months, stable from 2018 (22%), but indicating a continued increase over the past 10 
years (8% in 2009). Participants reported experiencing a stimulant overdose on a median of one 
occasion (IQR=1.00-1.25) (Figure 33). 
In 2019, participants reporting a non-fatal stimulant overdose in the past 12 months (n=22) were 
asked which stimulant drug they had used at the time of the last event, mainly nominating 
MDMA/ecstasy capsules (41%), MDMA/ecstasy pills (32%), and crystal methamphetamine (23%). Of 
participants who reported experiencing an adverse event while using a stimulant drug, 82% reported 
that they had also been under the influence of one or more additional drugs. On their last stimulant 
adverse event, 77% did not receive treatment or assistance; only a small number reporting receiving 
treatment (n≤5).   
Figure 33: Past year non-fatal stimulant and depressant overdose, Queensland,  2008-2019 
 
Note. Y axis has been reduced to 50% to improve visibility of trends. Data labels have been removed from figures in years of initial 
monitoring, and 2018 and 2019 with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Injecting Drug Use and Associated Risk Behaviours  
The proportion of the sample who reported ever injecting any drug in 2019 (11%) continued an overall 
decreasing trend since 2004 (32%), the small increase was not significant (Figure 34). Due to low 
numbers reporting recently injecting drugs, no further data are reported. For national trends refer to 
the National Report or contact the researchers for more information.  
Figure 34: Lifetime and past month drug injection, Queensland, 2004-2019 
  
Note. Y axis reduced to 50% to improve visibility of trends. Past 6-month injection asked of participants prior to 2016. Data labels have 
been removed from figures in years of initial monitoring, and 2018 and 2019 with small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; 
***p<0.001 for 2018 versus 2019. 
Drug Treatment 
In 2019, nine participants reported being in any form of drug treatment, indicating an increase from 
2018 (n≤5 and suppressed) and equally the highest proportion in the last 10 years. Among those in 
drug treatment, most were receiving drug counselling (n=7). For national trends, refer to the National 
Report, or for further information contact the researchers.  
Sexual Risk Behaviours 
Nearly all participants (98%) reported having penetrative sex with at least one partner in the six 
months preceding interview. In 2019, participants were asked about any penetrative sex, whether 
with a regular or casual partner, whereas in previous years, participants had been asked about casual 
partners only. Penetrative sex was defined as ‘penetration by penis or hand of the vagina or anus’. 
Given the sensitive nature of these questions, participants were given the option of self-completing 
this section of the interview (Table 4).  
Of those who reported having penetrative sex in the last six months, the majority (93%) reported 
having penetrative sex without a barrier (condom or dam) and 84% reported penetrative sex without 
a barrier while using alcohol and/or other drugs. About one third (34%) reported using a condom or 
dam the last time they engaged in penetrative sex while using alcohol/drugs (Table 4).  
In 2019, 51% of the sample reported having a sexual health check-up in the past year, similar to 42% 
in 2018; 19% had done so more than one year ago (15% in 2018), and 30% had never had a sexual 
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health check-up (marginally fewer than 43% in 2018; p=0.056). Amongst the former group, 84% 
reported that they had not received a positive diagnosis for a sexually transmitted infection (STI); 6% 
had received a positive diagnosis in the past year; and 10% had received a positive diagnosis over 
one year ago (Table 4).   
Table 4: Sexual health practices, Queensland, 2019 
 QLD 
 N=100 
Any penetrative sex in the past six months % (n) 98 (98) 
Of those who responded#:  N=91 
% Had penetrative sex without a barrier and did not know HIV/STI status of partner  46 
Of those who responded#: N=97 
% Drugs and/or alcohol impaired their ability to negotiate their wishes during sexual intercourse 31 
Of the total QLD sample (past 12 months): N=100 
% Had a sexual health check 51 
% Diagnosed with a sexually transmitted infection# - 
Note. Don’t know and did not respond responses excluded. # Due to the sensitive nature of these items there is missing data for some 
participants who chose not to respond. 
Mental Health  
A majority of participants (62%) self-reported that they had experienced a mental health problem in 
the preceding six months (other than drug dependence), continuing a rising trend since 2016, and 
double the proportion reporting mental health problem(s) in 2008 (31%; p<0.001). Of those who 
commented in 2019 (n=60), the most common mental health problem was anxiety (78%), followed by 
depression (72%). Smaller proportions reported Attention Deficit Hyperactivity Disorder (ADHD) 
(17%) and Post Traumatic Stress Disorder (PTSD) (12%); all other disorders were reported by fewer 
than five participants. Two-thirds (67%) of those who reported experiencing a mental health problem 
(42% of the total sample) reported seeing a mental health professional during the past six months, 
similar to 65% in 2018. Of these participants (n=42), 43% reported being prescribed medication for 
this problem in this period (41% in 2018) (Figure 35).  
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Figure 35: Self-reported mental health problems and treatment seeking in the past six months, 
Queensland, 2008-2019 
 
Note. The combination of the percentage who report treatment seeking and no treatment is the percentage who reported experiencing a 
mental health problem in the past six months. Data labels have been removed from figures with small cell size (i.e. n≤5 but not 0). *p<0.050; 
**p<0.010; ***p<0.001 for 2018 versus 2019. 
Crime  
Rates of past month criminal activity have fluctuated over time, with drug dealing and property crime 
the two main forms of criminal activity in 2019 (40% and 24%, respectively). Fifteen per cent of the 
sample reported having been arrested in the 12 months preceding interview, compared to 11% in 
2018. Among those arrested in 2019, the main reasons for arrest were drunk and disorderly (33%) 
drug use or possession (27%), and property crime (20%). Very low numbers (n≤5) reported having 
ever been in prison in 2019, consistent with previous years (Figure 36).  
Figure 36: Self-reported criminal activity in the past month, Queensland, 2003-2019 
 
Note. ‘Any crime’ comprises the percentage who report any property crime, drug dealing, fraud and/or violent crime in the past month. Y 
axis has been reduced to 60% to improve visibility of trends. Data labels have been removed from figures in 2003, 2018 and 2019 with 
small cell size (i.e. n≤5 but not 0). *p<0.050; **p<0.010; ***p<0.001 for 2018 versus 2019. 
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Modes of Purchasing Illicit or Non-Prescribed Drugs  
In interviewing and reporting, ‘online sources’ were defined as either surface or darknet marketplaces.  
In 2019, the most popular means of arranging the purchase of illicit or non-prescribed drugs in the 12 
months preceding interview in 2019 were via social networking applications (e.g. Facebook, Wickr, 
WhatsApp, Snapchat, Grindr, Tinder) (82%) and face-to-face (81%). Participants reported having 
obtained drugs via the darknet in the past year (21%) and 8% had purchased drugs on the surface 
web (Table 5).  
When asked to choose their main purchasing approach in the previous 12 months, the largest 
proportion nominated social networking applications (57%), followed by face-to-face (29%) (Table 5).  
When asked about how they had received illicit drugs on any occasion in the last 12 months, the 
majority of participants reported face-to-face (94%), with smaller numbers who reported receiving 
drugs by post (24%) and using a collection point (11%).  
Buying Drugs Online  
Twenty-one percent of participants reported purchasing drugs on the darknet in the previous 12 
months. We asked the remaining participants about their knowledge of the darknet and among those 
that commented (n=71), 52% had heard of it but had never accessed or researched it, 17% had 
researched it but never accessed it, and 31% had accessed it, but had never purchased from it.  
Of those that had purchased drugs via surface or darknet markets in the past 12 months (n=21), 29% 
had done so more than five times during this period. Of those who had purchased drugs online (n=31), 
the most commonly reported purchased drugs via online sources in the past 12 months was ecstasy 
(32%; n=10) followed by cannabis (28%; n=9). Of those who reported purchasing drugs via the 
surface or darknet in the last 12 months, 41% (n=13) reported doing so for later supply to others and 
23% (n=7) reported doing so to sell the drugs for profit.  
Selling Drugs Online  
Considering low numbers reported selling drugs online (n≤5), please refer to the National Report for 
national trends, or for further information, contact the research team.  
Table 5: Purchasing approaches of illicit drugs, Queensland, 2019 
Modes of purchase, last 12 months (%) 2019 
 n=109 
% Purchasing approaches  
 Face to face 81 
 Surface web 8 
 Darknet market 21 
Social networking applications 82 
Text messaging 43 
Phone call 35 
% Main purchasing approach  
 Face to face 29 
 Surface web 0 
 Darknet market 3 
Social networking applications 57 
Text messaging 9 
Phone call 2 
 
